Secins – Cytohesin Inhibitors
Compounds for the inhibition of EGFR-signalling.
Invention: Pharmacological inhibition of cell proliferation, adhesion and migration is pivotal in the treatment of a wide variety of cancers. A prominent protein involved in these processes and associated with the onset of cancer in humans is the EGF receptor. It was surprisingly found by the inventors that cytohesins are a pathophysiologically relevant class of cytoplasmatic EGFR activators. Therefore, they are an attractive target for the modulation of different disease-relevant signal transduction pathways. A correlation of cytohesin expression with EGFR-signalling could already be shown for human lung adenocarcinoma. By cytohesin inhibition, therapeutic interventions may be possible in the future. The present invention discloses small molecules which combine a highly selective inhibitory effect on cytohesins with cell permeability and low toxicity.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Sea slugs inspire highly stretchable biomedical sensor
USC Viterbi School of Engineering researcher Hangbo Zhao presents findings on highly stretchable and customizable microneedles for application in fields including neuroscience, tissue engineering, and wearable bioelectronics. The revolution in…
Twisting and binding matter waves with photons in a cavity
Precisely measuring the energy states of individual atoms has been a historical challenge for physicists due to atomic recoil. When an atom interacts with a photon, the atom “recoils” in…
Nanotubes, nanoparticles, and antibodies detect tiny amounts of fentanyl
New sensor is six orders of magnitude more sensitive than the next best thing. A research team at Pitt led by Alexander Star, a chemistry professor in the Kenneth P. Dietrich…
